Related Experiment Video
Updated: Sep 1, 2025

04:48
Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry CE-ICP-MS for Quantification of Iron Redox Species FeII, FeIII
Published on: May 4, 2020
8.2K
Melatonin: Potential avenue for treating iron overload disorders.
Jiancheng Yang1, Qinghua Tang1, Yuhong Zeng1
1Department of Osteoporosis, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
Ageing Research Reviews
|August 12, 2022
Summary
Melatonin, a potent antioxidant, shows promise in treating iron overload disorders by chelating iron and reducing oxidative damage. This offers a potential complementary therapy for conditions linked to iron dysregulation.
Area of Science:
- Biochemistry
- Pharmacology
- Oxidative Stress Research
Background:
- Iron overload is a significant risk factor in numerous chronic diseases.
- Current iron chelators have poor patient adherence due to side effects.
- Melatonin exhibits iron-chelating and antioxidant properties.
Purpose of the Study:
- To review iron overload research.
- To analyze melatonin's therapeutic potential for iron overload.
- To discuss melatonin's protective effects against iron-induced oxidative damage.
Main Methods:
- Literature review of iron overload studies.
- Analysis of melatonin's iron-chelating capacity.
- Examination of melatonin's antioxidant mechanisms.
Main Results:
- Melatonin demonstrates significant iron chelation ability.
- Melatonin possesses direct free radical scavenging activity.
- Melatonin inhibits iron overload-induced lipid peroxidation.
Conclusions:
- Melatonin is a potential complementary therapy for iron overload disorders.
- Melatonin's iron-chelating and antioxidant activities are key therapeutic mechanisms.
- Further research into melatonin may aid in managing iron homeostasis disorders.
Keywords:
AntioxidantIron chelatingIron metabolismIron overloadMelatoninNeurodegenerative diseasesReactive oxygen speciesMore Related Videos
Related Concept Videos
Management of Insomnia
314
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
314
Sedatives and Hypnotics Drugs: Miscellaneous Agents
232
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
232
Major Hormones and Their Functions
658
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
658

